Damora Therapeutics (DMRA) Net Equity Issued and Repurchased (2020 - 2023)

Damora Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $171000.0 for Q3 2023.

• Quarterly Net Equity Issued and Repurchased fell 59.67% year-over-year to $171000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $2.9 million (up 488.14% YoY) and the FY2023 annual result came in at $2.9 million, up 467.26% from the prior year.
• Net Equity Issued and Repurchased was $171000.0 for Q3 2023 at Damora Therapeutics, down from $2.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $39.7 million in Q1 2020 and bottomed at -$19.1 million in Q4 2020.
• A 3-year average of $4.8 million and a median of $171000.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 59.67% in 2023, while the deepest fall reached 59.67% in 2023.
• Damora Therapeutics' Net Equity Issued and Repurchased stood at -$19.1 million in 2020, then surged by 100.34% to $65000.0 in 2022, then soared by 163.08% to $171000.0 in 2023.
• Business Quant data shows DMRA's Net Equity Issued and Repurchased at $171000.0 in Q3 2023, $2.7 million in Q2 2023, and $23000.0 in Q1 2023.